1. Home
  2. WEAV vs MYGN Comparison

WEAV vs MYGN Comparison

Compare WEAV & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weave Communications Inc.

WEAV

Weave Communications Inc.

HOLD

Current Price

$6.32

Market Cap

600.1M

Sector

Technology

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$7.02

Market Cap

625.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEAV
MYGN
Founded
2011
1991
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
600.1M
625.5M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
WEAV
MYGN
Price
$6.32
$7.02
Analyst Decision
Strong Buy
Hold
Analyst Count
5
13
Target Price
$12.20
$12.58
AVG Volume (30 Days)
1.5M
1.3M
Earning Date
10-30-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$229,790,000.00
$825,300,000.00
Revenue This Year
$19.19
$0.06
Revenue Next Year
$15.09
$5.68
P/E Ratio
N/A
N/A
Revenue Growth
17.34
0.21
52 Week Low
$5.64
$3.76
52 Week High
$17.63
$16.83

Technical Indicators

Market Signals
Indicator
WEAV
MYGN
Relative Strength Index (RSI) 48.71 47.63
Support Level $6.24 $6.43
Resistance Level $6.46 $8.09
Average True Range (ATR) 0.22 0.42
MACD 0.06 0.07
Stochastic Oscillator 78.74 44.14

Price Performance

Historical Comparison
WEAV
MYGN

About WEAV Weave Communications Inc.

Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses, that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more, enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and revenue from subscription services.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.

Share on Social Networks: